Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma

IntroductionThe programmed death-1 (PD-1) immune checkpoint inhibitor pembrolizumab is currently approved in the US for the first-line (1L) treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), either alone or in combination with platinum and 5-fluorouracil (5-FU)....

Полное описание

Библиографические подробности

Главные авторы:	Christopher M. Black, Dandan Zheng, Gleicy M. Hair, Lei Ai, Liya Wang, Daisuke Goto, Nati Lerman, Behzad Bidadi, Glenn J. Hanna
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2024-02-01
Серии:	Frontiers in Oncology
Предметы:	head and neck squamous cell carcinoma antineoplastic agents PD-1 taxanes Kaplan-Meier estimate patient outcomes
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1348045/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!